Targeting uPAR by CRISPR/Cas9 System Attenuates Cancer Malignancy and Multidrug Resistance

PLAUR Confers Resistance to Gefitinib Through EGFR/P-AKT/Survivin Signaling Pathway

(2018) Jian Zhou et al.   CELLULAR PHYSIOLOGY AND BIOCHEMISTRY

CRISPR/Cas9 nickase mediated targeting of urokinase receptor gene inhibits neuroblastoma cell proliferation

(2018) Karina D. Rysenkova et al.   Oncotarget

Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications

(2018) Niaz Mahmood et al.   Frontiers in Oncology

Inhibition of WEE1 Suppresses the Tumor Growth in Laryngeal Squamous Cell Carcinoma

(2018) Meng-Ling Yuan et al.   Frontiers in Pharmacology

Targeting genomic rearrangements in tumor cells through Cas9-mediated insertion of a suicide gene

(2017) Zhang-Hui Chen et al.   NATURE BIOTECHNOLOGY

Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9

(2017) Jiangtao Ren et al.   Protein & Cell

Randomized phase II trial with an uPA inhibitor (WX-671) in patients with locally advanced nonmetastatic pancreatic cancer.

(2017) V. Heinemann et al.   JOURNAL OF CLINICAL ONCOLOGY

Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition

(2016) Jiangtao Ren et al.   CLINICAL CANCER RESEARCH

A Genome-wide CRISPR Screen Identifies CDC25A as a Determinant of Sensitivity to ATR Inhibitors

(2016) Sergio Ruiz et al.   MOLECULAR CELL

Applications of CRISPR technologies in research and beyond

(2016) Rodolphe Barrangou et al.   NATURE BIOTECHNOLOGY

Cornerstones of CRISPR–Cas in drug discovery and therapy

(2016) Christof Fellmann et al.   NATURE REVIEWS DRUG DISCOVERY

Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations

(2016) Axel Hoos   NATURE REVIEWS DRUG DISCOVERY

Multiplexed pancreatic genome engineering and cancer induction by transfection-based CRISPR/Cas9 delivery in mice

(2016) Roman Maresch et al.   Nature Communications

Genome-wide CRISPR Screen in a Mouse Model of Tumor Growth and Metastasis

(2015) Sidi Chen et al.   CELL

Sequential cancer mutations in cultured human intestinal stem cells

(2015) Jarno Drost et al.   NATURE

Modeling colorectal cancer using CRISPR-Cas9–mediated engineering of human intestinal organoids

(2015) Mami Matano et al.   NATURE MEDICINE

Antibody-modified T cells: CARs take the front seat for hematologic malignancies

(2014) M. V. Maus et al.   BLOOD

CRISPR-mediated direct mutation of cancer genes in the mouse liver

(2014) Wen Xue et al.   NATURE

Overexpression of CD147 contributes to the chemoresistance of head and neck squamous cell carcinoma cells

(2013) Zhiquan Huang et al.   JOURNAL OF ORAL PATHOLOGY & MEDICINE

Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells

(2013) Ophir Shalem et al.   SCIENCE

Role of Urokinase Receptor in Tumor Progression and Development

(2013) Hyangsoon Noh et al.   Theranostics

A transformation in the mechanism by which the urokinase receptor signals provides a selection advantage for estrogen receptor-expressing breast cancer cells in the absence of estrogen

(2012) Boryana M. Eastman et al.   CELLULAR SIGNALLING

Development of Novel Therapeutics Targeting the Urokinase Plasminogen Activator Receptor (uPAR) and Their Translation Toward the Clinic

(2011) Andrew P. Mazar et al.   CURRENT PHARMACEUTICAL DESIGN

Targeting the Urokinase Plasminogen Activator Receptor Inhibits Ovarian Cancer Metastasis

(2010) H. A. Kenny et al.   CLINICAL CANCER RESEARCH

Regulation of cell signalling by uPAR

(2009) Harvey W. Smith et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

A cyclic peptidylic inhibitor of murine urokinase-type plasminogen activator: changing species specificity by substitution of a single residue

(2008) Lisbeth M. Andersen et al.   BIOCHEMICAL JOURNAL